BCKDK and breast carcinoma: First, BCKDK is negatively associated with a low recurrence-free survival rate [25], and genetic ablation or inhibition of BCKDK synergizes the cell cycle arrest effects of paclitaxel and increases cell death in breast cancer cells [20,24].